Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.39 USD
+0.07 (5.30%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CHRS 1.39 +0.07(5.30%)
Will CHRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHRS
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
Other News for CHRS
Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)
Coherus Biosciences just downgraded at UBS, here's why
Coherus Biosciences: Hold Rating with Downward Revenue Projections and Price Target Revision
UBS cuts Coherus to neutral, cites limited growth opportunities
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects